These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34619517)

  • 21. [Counterfeit phosphodiesterase type 5 inhibitors--growing safety risks for public health].
    Fijałek Z; Sarna K; Błazewicz A; Marin J
    Rocz Panstw Zakl Hig; 2010; 61(3):227-35. PubMed ID: 21365856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recreational use of phosphodiesterase type 5 inhibitors by healthy young men.
    Bechara A; Casabé A; De Bonis W; Helien A; Bertolino MV
    J Sex Med; 2010 Nov; 7(11):3736-42. PubMed ID: 20722788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor-Quality and Counterfeit Drugs: A Systematic Assessment of Prevalence and Risks Based on Data Published From 2007 to 2016.
    Koczwara A; Dressman J
    J Pharm Sci; 2017 Oct; 106(10):2921-2929. PubMed ID: 28549909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
    Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
    Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PDE5 inhibitors: considerations for preference and long-term adherence.
    Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
    Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Public Health Implications of Counterfeit Medications.
    Fantasia HC; Vooys KM
    Nurs Womens Health; 2018 Jun; 22(3):264-268. PubMed ID: 29885715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Treatment for Premature Ejaculation in the Light of Currently Used Therapies: A Review.
    Porst H; Burri A
    Sex Med Rev; 2019 Jan; 7(1):129-140. PubMed ID: 30057136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
    Shkolyar E; Li S; Tang J; Eisenberg ML
    J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia.
    Alshahrani S; Ahmed AF; Gabr AH; Al Ansari A; El-Feky M; Elbadry MS
    Arab J Urol; 2016 Jun; 14(2):94-100. PubMed ID: 27489735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses.
    Pyrgidis N; Mykoniatis I; Haidich AB; Tirta M; Talimtzi P; Kalyvianakis D; Ouranidis A; Hatzichristou D
    BMJ Open; 2021 Aug; 11(8):e047396. PubMed ID: 34429310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME).
    Shindel AW
    J Sex Med; 2009 Jul; 6(7):1794-808; quiz 1793, 1809-10. PubMed ID: 19575771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening sexual performance enhancing compounds and their analogues in counterfeit and illicit erectile dysfunction drugs by high-performance liquid chromatography and liquid chromatography-tandem mass spectrometry.
    Lee JH; Han JH; Kim S; Kim NS; Yoon CY; Kim J; Baek SY
    J Forensic Leg Med; 2021 Aug; 82():102224. PubMed ID: 34371245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Counterfeit medicines in Poland: opinions of primary healthcare physicians, nurses and lay persons.
    Binkowska-Bury M; Januszewicz P; Wolan M; Sobolewski M; Krauze M; Fijalek ZE
    J Clin Nurs; 2013 Feb; 22(3-4):559-68. PubMed ID: 22805373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase type 5 inhibitors: unmet needs.
    Hatzimouratidis K; Hatzichristou DG
    Curr Pharm Des; 2009; 15(30):3476-85. PubMed ID: 19860693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Counterfeit drugs as a gobal threat to health].
    Golocorbin Kon S; Mikov M
    Med Pregl; 2011; 64(5-6):285-90. PubMed ID: 21789919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the Prevalence of Using Suspected Counterfeit Medications in the General Population.
    Jewell JS; Bemis EA; Black JC
    J Addict Med; 2024 Jul-Aug 01; 18(4):466-469. PubMed ID: 38832681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction.
    Canguven O; Bailen J; Fredriksson W; Bock D; Burnett AL
    J Sex Med; 2009 Sep; 6(9):2561-7. PubMed ID: 19627462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors.
    Schnetzler G; Banks I; Kirby M; Zou KH; Symonds T
    J Sex Med; 2010 Mar; 7(3):1237-46. PubMed ID: 20136707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substandard and counterfeit medicines: a systematic review of the literature.
    Almuzaini T; Choonara I; Sammons H
    BMJ Open; 2013 Aug; 3(8):e002923. PubMed ID: 23955188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.